If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Keith G. Harding CBE FRCGP FRCP FRCS FLSW is a British physician. Harding graduated from Birmingham University with an MBChB degree in Medicine in 1976. Harding is the Director of TIME Institute (Translation, Innovation, Methodology and Engagement) and Head of the Wound Healing Research Unit in the School of Medicine at Cardiff University. He is Clinical Lead for Wound Healing in the Cardiff & Vale NHS Trust. In September 2013 Harding was appointed Dean of Clinical Innovation at Cardiff University. From 2002 to 2005 he was Head of the Department of Surgery at Cardiff University. He is Editor-in-Chief of the International Wound Journal. Keith Harding is a Past President of the European Tissue Repair Society. He was the first President of the European Pressure Ulcer Advisory Panel, and first Recorder of the European Wound Management Association. Harding was Chair of the International Working Group on Wound Healing in Diabetic Foot Disease in 2003. He was Chair of the Expert Working Group that produced a range of International Consensus Documents from 2004 to 2011. Professor Harding was appointed a Commander of the Order of the British Empire in the 2013 New Year Honours for services to medicine and healthcare. Harding is a Fellow of the Royal College of General Practitioners, a Fellow of the Royal College of Physicians, and a Fellow of the Royal College of Surgeons. In 2014, Professor Harding was elected a Fellow of the Learned Society of Wales.
Saeujeot (새우젓) or myeolchijeot is not added to the kimchi spice-seasoning mixture, but is simmered first to reduce odors, eliminate tannic flavor and fats, and then is mixed with a thickener made of rice or wheat starch (풀). This technique has been falling into disuse in the past 40 years.
For a more accurate determination of the molecular weight, the relative migration distances of the individual protein bands are measured in the separating gel. The measurements are usually performed in triplicate for increased accuracy. The relative mobility (called Rf value or Rm value) is defined as the distance migrated by the protein band divided by the distance migrated by the buffer front. The distances are each measured from the beginning of the separation gel. The migration of the buffer front roughly corresponds to the migration of the dye contained in the sample buffer. The Rf's of the size marker are plotted semi-logarithmically against their known molecular weights. By comparison with the linear part of the generated graph or by a regression analysis, the molecular weight of an unknown protein can be determined by its relative mobility. Bands of proteins with glycosylations can be blurred, as glycosylation is often heterogenous. Proteins with many basic amino acids (e.g. histones) can lead to an overestimation of the molecular weight or even not migrate into the gel at all, because they move slower in the electrophoresis due to the positive charges or even to the opposite direction. On the other hand, many acidic amino acids can lead to accelerated migration of a protein and an underestimation of its molecular mass.
Sources: en.wikipedia.org
== See also == Resonance-enhanced multiphoton ionization Rydberg ionization spectroscopy Photoionization Atmospheric-pressure laser ionization Radiometric dating Electron excitation Tunable lasers Cosmochemistry
When in point detonate mode the projectile's high explosive detonates when it hits a target. In point detonate delay mode the high explosive detonates a brief instant after it hits a target. The delay is intended to let the projectile first penetrate a wall, and explode when it emerges on the other side. In air burst mode the cannon's aiming system programs the munition to explode in the air above the target. When the gunner aims their sight on the desired target, and presses their trigger halfway, the aiming system calculates the range to the target. They can then raise their sight slightly above the target, and when they pull the trigger all the way the aiming system will instruct the round to explode in the air above the target. Enemies hiding behind an obstacle can then be killed or wounded without blowing a hole through the obstacle. The XM1203 Armor Piercing Fin Stabilized Discarding Sabot with Tracer. The projectile itself is 50 mm in diameter, encasing a long thin dart, designed to pierce armored vehicles. A light "sabot" grips the barrel's rifling, in order for the shell to get the full power of the expanding gas. Tracer rounds have a button of pyrotechnic chemical that leaves a trail to help a gunner observe the trajectory/path of the shot. The XM1202 Target Practice-Tracer round is a full-bore training round 50 mm in diameter. With the intended purpose of drill firing and gun ballistic tests, the XM1202 round likely shares similar ballistic performance to the XM1204 HEAB-T round.
The app's operator suggested in court documents pertaining to its lawsuit to overturn the order that the retaliation was also for a ticket reservation prank waged by some users of the video platform that depressed attendance for a campaign rally he held in Tulsa, Oklahoma, that June. The executive order was blocked by federal courts in two separate cases on grounds that the sanctions likely violated IEEPA's informational materials exemption (under the Berman Amendment) and First Amendment protections applying to users of the apps. In February 2026, the Supreme Court held that the IEEPA did not authorize the president to set tariffs in Learning Resources, Inc. v. Trump. This decision reversed the tariffs implemented by Trump under IEEPA during his second term. Consequently, U.S. Customs established a new process—the Consolidated Administration & Processing of Entries (CAPE) system—to refund importers for voided IEEPA duties.
=== Neuromyotonia === Neuromyotonia refers to muscle twitching and cramping at rest that is exacerbated with exercise. It is caused by sustained or repetitive spontaneous muscle activity of peripheral nerve origin. Myokymia, or spontaneous rippling and twitching movements of muscles, is a visible component of neuromyotonia. Electromyography (EMG) discloses spontaneous, repetitive motor unit or single fiber discharges firing in irregular rhythmic bursts at high intraburst frequencies. Some of the muscles exhibiting twitching include the bilateral gastrocnemii, quadriceps femoris, biceps brachii, and right masseter. In vivo electrophysiological studies suggest at least some dysfunction of the muscle cell membrane. In the examined muscles, no abnormal insertional activity or fibrillation potentials were noted. Nerve conduction studies were normal.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.